Comparison of once-weekly teriparatide and alendronate against new osteoporotic vertebral fractures at week 12

Ikeda, Satoshi; Nakamura, Eiichiro; Narusawa, Kenichiro; Fukuda, Fumio; Matsumoto, Hidehiro; Nakai, Kenichiro; Sakata, Toshiie; Yoshioka, Toru; Fujino, Yoshihisa; Sakai, Akinori; Investigators, Kotu T-Wrap Study

doi:10.1007/s00774-019-01023-x

Cited by 10 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, the progression of VC is related to the severity of OVF at baseline. Recent comparative studies between BP and TPTD have shown similar progression of VC ( Ikeda et al, 2020 ; Iwata et al, 2017 ). Studies have concluded that VC progresses immediately after a fracture ( Ikeda et al, 2020 ), and thus it can occur before osteoanabolic agents have an effect on vertebral mechanical strength.…”

Section: Discussionmentioning

confidence: 94%

“…Several studies have demonstrated the advantages of TPTD over BP or naïve in terms of VC progression, bone healing, and pain ( Ikeda et al, 2020 ; Iwata et al, 2017 ; Kitaguchi et al, 2019 ; Nair et al, 2023 ; Tsuchie et al, 2016 ). In particular, several reports have demonstrated earlier bone union after treatment with TPTD than with BP ( Kitaguchi et al, 2019 ; Nair et al, 2023 ; Shigenobu et al, 2019 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of osteoanabolic agents (teriparatide and romosozumab) with bisphosphonates in prevention of subsequent vertebral fractures in patients treated for osteoporotic vertebral fracture for 12 months: An observational cohort study

Maruo,

Kusukawa,

Toi

et al. 2024

Bone Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Comparison of osteoanabolic agents (teriparatide and romosozumab) with bisphosphonates in prevention of subsequent vertebral fractures in patients treated for osteoporotic vertebral fracture for 12 months: An observational cohort study

Maruo,

Kusukawa,

Toi

et al. 2024

Bone Reports

View full text Add to dashboard Cite

“…The effects of bed rest may have been confounded by the use of osteoporosis medications, which were not standardized in this study. Reports on the effects of teriparatide on vertebral collapse progression and OVF union have been conflicting [41][42][43][44][45][46][47] . However, the administration of bisphosphonates has been reported not to influence bone union after OVF 48,49 .…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Effects of Conservative Treatment with 2-Week Bed Rest for Osteoporotic Vertebral Fractures

Funayama

Tatsumura

Fujii

et al. 2022

Journal of Bone and Joint Surgery

View full text Add to dashboard Cite

UpdateThis article was updated on October 19, 2022, because of previous errors, which were discovered after the preliminary version of the article was posted online. On page 1787, in the legend for Figure 2, the sentence that had read “The vertebral collapse rate (in %) was defined as 1 − (A/P) × 100, and vertebral instability (in %) was defined as the difference in vertebral collapse rate between the loaded and non-loaded images.” now reads “The vertebral collapse rate (in %) was defined as (1 − [A/P]) × 100, and vertebral instability (in %) was defined as the difference in vertebral collapse rate between the loaded and non-loaded images.” On page 1788, in the section entitled “Data Collection,” the sentence that had read “The vertebral collapse rate (in %) was defined as 1 − (anterior vertebral wall height/posterior vertebral wall height) × 100, and vertebral instability (in %) was defined as the difference in vertebral collapse rate between the loaded and non-loaded images9.” now reads “The vertebral collapse rate (in %) was defined as (1 − [anterior vertebral wall height/posterior vertebral wall height]) × 100, and vertebral instability (in %) was defined as the difference in vertebral collapse rate between the loaded and non-loaded images9.” Finally, on page 1791, in Table IV, the footnote for the “Primary outcome” row that had read “N = 113 in the rest group and 99 in the no-rest group.” now reads “N = 116 in the rest group and 108 in the no-rest group.”

show abstract

“…The improvement in back pain was sustained for at least 12 months after the teriparatide treatment was discontinued [ 47 ]. Further studies have reported better fracture site pain in teriparatide treated patients in comparison to bisphosphonates [ [48] , [49] , [50] ]. Akhter et al‘s systematic review and meta-analysis found high quality evidence to support the use of teriparatide 20 mcg daily injected dose to improve pain severity relative to all comparators [ 50 ].…”

Section: Pharmacology Approach In Vertebral Fragility Fracturesmentioning

confidence: 99%

Pharmacological options for pain control in patients with vertebral fragility fractures

Tanna

Ong

2022

Osteoporosis and Sarcopenia

View full text Add to dashboard Cite

Comparison of once-weekly teriparatide and alendronate against new osteoporotic vertebral fractures at week 12

Cited by 10 publications

References 29 publications

Comparison of osteoanabolic agents (teriparatide and romosozumab) with bisphosphonates in prevention of subsequent vertebral fractures in patients treated for osteoporotic vertebral fracture for 12 months: An observational cohort study

Comparison of osteoanabolic agents (teriparatide and romosozumab) with bisphosphonates in prevention of subsequent vertebral fractures in patients treated for osteoporotic vertebral fracture for 12 months: An observational cohort study

Therapeutic Effects of Conservative Treatment with 2-Week Bed Rest for Osteoporotic Vertebral Fractures

Pharmacological options for pain control in patients with vertebral fragility fractures

Contact Info

Product

Resources

About